Although the multitude of pathways involved in the pathogenesis of systemic lupus erythematosus (SLE) seem to be interconnected, each predominates in only a fraction of patients. This complexity means that many agents tested in SLE clinical trials — now including iberdomide — produce only a small clinical benefit.

中文翻译：

---

Ikaros、Aiolos 和其他治疗 SLE 的移动目标

尽管参与系统性红斑狼疮 (SLE) 发病机制的众多途径似乎相互关联，但每种途径仅在一小部分患者中占主导地位。这种复杂性意味着在 SLE 临床试验中测试的许多药物——现在包括伊伯多胺——仅产生很小的临床益处。